足癣治疗市场 - 药物类别、疾病类型、给药途径、类型、年龄层、配销通路、全球预测

由于治疗方法的快速进步和 RampD 投资的增加，全球足癣治疗市场在 2024 年至 2032 年间的复合年增长率将达到 4.3%。微针贴片等创新疗法为传统抗真菌药物提供了有效且便利的替代方案，可改善患者的治疗效果。

RampD 投资的增加也推动了新型药物输送系统和更有效治疗方法的发现，以应对不断上升的真菌感染发病率。这些进步正在提高治疗效果、患者依从性和市场可近性，进一步促进市场扩张。例如，2023年7月，香港大学李嘉诚医学院临床医学院骨科及创伤学系的Kelvin Yeung领导的研究团队开发了一种新的微针贴片，为患者提供有效的非抗生素治疗治疗皮肤感染，包括足癣。

该行业分为药物类别、疾病类型、给药途径、类型、年龄层、配销通路和地区。

从给药途径来看，由于处方药的功效和可靠性，到 2032 年，处方药领域的足癣治疗市场将显着扩张。与非处方药相比，这些治疗方法通常含有更高浓度的活性成分，可以更有效、更快速地缓解症状。医疗保健专业人士也经常建议持续或严重病例的处方治疗。

根据配销通路，零售药房领域的足癣治疗行业将在 2032 年获得可观的收益，这要归功于其广泛的可及性和便利性，为寻求非处方药和处方药的消费者提供便利。零售药局提供多种治疗选择，从外用药膏到口服抗真菌药，使患者可以轻鬆获得必要的治疗。随着医疗保健意识和对有效治疗的需求不断增长，对零售药局的偏好将进一步上升。

在人口快速增长、真菌感染发病率增加以及足部卫生意识不断提高的推动下，亚太地区足癣治疗市场从 2024 年到 2032 年将出现显着的复合年增长率。该地区不断扩大的医疗基础设施和更高的可支配收入使人们能够更多地获得非处方药和处方药治疗。此外，主要市场参与者的存在和治疗方案的持续进步将有助于区域产业的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 足癣盛行率增加
    • 有效非处方药的可用性
    • 人们对足癣及其症状的认识不断提高
  • 产业陷阱与挑战
    • 抗真菌药物抗药性增加
    • 替代治疗方案的可用性
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

• 主要趋势
• 抗霉菌药
• 组合药物

第 6 章：市场估计与预测：按疾病类型，2021 - 2032

• 主要趋势
• 指间足癣
• 足底足癣
• 水泡性足癣
• 急性溃疡性足癣

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

• 主要趋势
  • 专题
  • 奶油
  • 凝胶
  • 洗剂
  • 粉末
  • 喷
  • 口服

第 8 章：市场估计与预测：按类型 2021 - 2032

• 主要趋势
• 非处方药
• 处方药

第 9 章：市场估计与预测：按年龄划分，2021 - 2032

• 主要趋势
• 18岁以下
• 19 - 35 岁
• 36 - 50 岁
• 51岁以上

第 10 章：市场估计与预测：按配销通路，2021 - 2032

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 11 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 12 章：公司简介

• Bausch Health Companies Inc.
• Bayer AG
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Limited
• Pfizer, Inc.
• Sebela Pharmaceuticals Holdings Inc.
• Smith & Nephew plc
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Limited
• Viatris Inc.

Global Tinea Pedis Treatment Market will register 4.3% CAGR between 2024 and 2032, owing to rapid advancements in treatment methods and increased R&D investments. Innovative therapies, such as microneedle patches, are providing effective and convenient alternatives to traditional antifungal medications for enhancing patient outcomes.

Increased R&D investments are also fuelling the discovery of novel drug delivery systems and more potent treatments for addressing the rising incidence of fungal infections. These advancements are improving treatment efficacy, patient compliance, and market accessibility, further contributing to the market expansion. For instance, in July 2023, a research team headed by Kelvin Yeung from the Department of Orthopaedics and Traumatology at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong HKUMed developed a new microneedle patch for offering an effective non-antibiotic treatment for skin infections, including tinea pedis.

The industry is segmented into drug class, disease type, route of administration, type, age group, distribution channel, and region.

By route of administration, the tinea pedis treatment market from the prescription segment will witness remarkable expansion through 2032 due to the efficacy and reliability of prescription medications. These treatments often contain higher concentrations of active ingredients compared to over-the-counter OTC options for providing more effective and faster relief from symptoms. Healthcare professionals also frequently recommend prescription treatments for persistent or severe cases.

Based on distribution channel, the tinea pedis treatment industry from the retail pharmacies segment will garner considerable gains by 2032, attributed to their widespread accessibility and convenience for consumers seeking OTC and prescription medications. Retail pharmacies provide a variety of treatment options, from topical creams to oral antifungals, making it easy for patients to obtain necessary treatments. As healthcare awareness and the demand for effective treatments is growing, the preference for retail pharmacies will further rise.

Asia Pacific tinea pedis treatment market will witness a noteworthy CAGR from 2024 to 2032, propelled by the rapidly growing population, increasing incidence of fungal infections, and rising awareness about foot hygiene. The expanding healthcare infrastructure and higher disposable incomes of the region are enabling greater access to both OTC and prescription treatments. Additionally, the presence of major market players and ongoing advancements in treatment options will contribute to the regional industry growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of tinea pedis
    • 3.2.1.2 Availability of effective OTC drugs
    • 3.2.1.3 Growing awareness about tinea pedis and its symptoms
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Increased resistance to antifungal medications
    • 3.2.2.2 Availability of alternative treatment options
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Antifungals
• 5.3 Combination drugs

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Interdigital tinea pedis
• 6.3 Plantar tinea pedis
• 6.4 Vesicular tinea pedis
• 6.5 Acute ulcerative tinea pedis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
  • 7.1.1 Topical
  • 7.1.2 Cream
  • 7.1.3 Gel
  • 7.1.4 Lotion
  • 7.1.5 Powder
  • 7.1.6 Spray
  • 7.1.2 Oral

Chapter 8 Market Estimates and Forecast, By Type 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 OTC drugs
• 8.3 Prescription drugs

Chapter 9 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Below 18 years
• 9.3 19 - 35 years
• 9.4 36 - 50 years
• 9.5 51 years and above

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of Middle East and Africa

Chapter 12 Company Profiles

• 12.1 Bausch Health Companies Inc.
• 12.2 Bayer AG
• 12.3 GlaxoSmithKline plc
• 12.4 Glenmark Pharmaceuticals Limited
• 12.5 Pfizer, Inc.
• 12.6 Sebela Pharmaceuticals Holdings Inc.
• 12.7 Smith & Nephew plc
• 12.8 Sun Pharmaceutical Industries Ltd
• 12.9 Teva Pharmaceutical Industries Limited
• 12.10 Viatris Inc.